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EducationGabapentin, an AED approved for the adjunctive treatment of partial seizures with/without secondary generali-
zation and for the treatment of postherpetic neuralgia, is frequently used off-label for the treatment of both psy-
chiatric and pain disorders. Since gabapentin is cleared solely by renal excretion, dosing requires consideration of
the patient's renal function. Myoclonic activity may occur as a complication of gabapentin toxicity, especially
with acute kidney injury or end-stage renal disease. We report 2 cases of myoclonic activity associated with
gabapentin toxicity in the setting of renal disease which resolved with discontinuation of gabapentin and treat-
ment with hemodialysis and peritoneal dialysis. As gabapentin has multiple indications and off-label uses, an
understanding of myoclonus, neurotoxicity, and renal dosing is important to clinicians in multiple specialties.
© 2013 . Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Antiepileptic drugs (AEDs) are used in the treatment of epilepsy,
pain, and psychiatric disorders [1,2]. Hepatic and renal status may im-
pact the efﬁcacy and toxicity associated with AEDs which requires
awareness by clinicians in multiple specialties and appropriate dose
adjustments [3]. Gabapentin is an AED approved by the FDA for the
adjunctive treatment of partial seizures with/without secondary gener-
alization in children, adolescents, and adults and for the treatment of
postherpetic neuralgia [4]; the prodrug gabapentin enacarbil is ap-
proved by the FDA for the treatment of restless leg syndrome [5].
Gabapentin is frequently used off-label for the treatment of both psychi-
atric and pain disorders [1,4]. Gabapentin is not hepaticallymetabolizederms of the Creative Commons
which permits non-commercial
d the original author and source
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evier Inc. This is an open access articand is cleared solely by renal excretion; dosing requires consideration of
the patient's renal function, especially in the context of end-stage renal
disease (ESRD) [3,6,7]. We report 2 cases of myoclonic activity associat-
ed with gabapentin toxicity in the setting of renal disease and address
treatment with hemodialysis (HD) and peritoneal dialysis (PD).
2. Methods
Case analysis with PubMed literature review was employed.
3. Results
3.1. Case 1
A 78-year-old woman with congestive heart failure, history of
thromboembolism, hypertension, diabetes mellitus, hyperlipidemia,
asthma, diabetic peripheral neuropathy, and depression presented with
tremors involving her upper extremities for 3 days prior to admission.
The patient had no history of renal disease. Her admission medications
included simvastatin, metformin, citalopram, gabapentin, ﬂuticasone
proprionate inhaler, inhaled albuterol, lisinopril, furosemide, and meto-
lazone. Physical examination noted severe bilateral upper extremity
myoclonus with normal mental status and without other neurological
symptoms. Abnormal laboratory results on admission included a sodiumle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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(BUN) level of 91 mg/dL, a creatinine (Cr) level of 3.2 mg/dL, an elevated
BUN/Cr ratio of 28.44, and an estimated glomerular ﬁltration rate of
13 mL/min/1.73 m2. Evaluation revealed acute kidney injury (AKI) sec-
ondary to a recently increased furosemide total dose of 60 mg daily
and lisinopril 5 mg daily with hyperkalemia and azotemia. Prior to
admission, the patient had been chronically treated with gabapentin
900 mg total daily dose for neuropathic pain. With discontinuation of
gabapentin and initiation of HD,marked improvement in hermyoclonus
occurred. The patient received 2 sessions of HD andwas dischargedwith
normal renal function, a BUN level of 20 mg/dL andaCr level of 1.1 mg/dL,
and resolved myoclonus. Gabapentin was held on discharge.
3.2. Case 2
A 55-year-old man with ESRD on PD, anemia, diabetes mellitus,
hypertension, neuropathic pain, hyperlipidemia, hepatitis C, peripheral
vascular disease with recently amputated gangrenous toe on long-term
vancomycin and piperacillin/tazobactam, and acute pain syndrome
presented for evaluation of bilateral upper extremity tremors, altered
mental status, hypotension, and worsening leg infection. Following ini-
tiation of gabapentin 600 mg total daily dose for neuropathic pain
3 days prior to admission, the patient developed severe arm tremors
with the inability to hold objects, lethargy, and intermittent episodes
of confusion. His other admission medications included clopidogrel,
amlodipine, hydralazine, metoprolol, clonidine, atorvastatin, oxyco-
done, hydromorphone, sevelamer, lanthanum, epoetin, and insulin
glargine. Physical examination conﬁrmed bilateral upper extremity
myoclonus. Abnormal renal function on admission, with a BUN level
of 49 mg/dL and a Cr level of 12.7 mg/dL, was comparable to outpatient
renal function during the prior three months, with a BUN level of
50–52 mg/dL and a Cr level of 10.4–11.1 mg/dL, when the patient
did not have myoclonus. The patient's PD treatment was increased
from 4 to 6 exchanges daily. With increased dialysis and discontin-
uation of gabapentin, myoclonus and altered mental status resolved
within four days.
4. Discussion
These unique cases raise a series of important points speciﬁcally
related to these patients that should be considered in the general treat-
ment of patients with gabapentin and other AEDs that require renal
clearance.
First, a recent study of off-label prescriptions found the overall rate
to be 21%; however, AEDs as a class are higher at 46%, and gabapentin,
in particular, has the highest rate of all drugs with 83% prescribed off-
label [1,4,8]. Research supports the off-label use of gabapentin to treat
diabetic peripheral neuropathic pain [9,10]. One mechanism suggested
for the broad spectrum effects of gabapentin is voltage-sensitive calci-
um channel modulation [11].
Second, with normal renal function, the half-life of gabapentin
ranges from 5 to 7 h [12]. In patients with ESRD on non-HD days, one
study reported the gabapentin elimination half-life to be 132 h [12].
That study noted that 35% of a single gabapentin dose was removed
after three sessions of HD, supporting the use of HD in the treatment
of gabapentin toxicity [12].
Third, myoclonus is a known adverse effect associated with
gabapentin with a prevalence as high as 12.5% which, depending on
severity, may not interfere with AED therapy [13]. In the context of
renal failure, myoclonus and neurotoxicitymay require discontinuation
of gabapentin [6]. Most reports demonstrate that serum concentrations
greater than 15 μg/mL are associated with symptomatic toxicity [14]. In
patients who have intact renal function, toxicities are uncommon as
gabapentin is rapidly cleared based on its short half-life; however,
gabapentin concentrations are signiﬁcantly increased in patients with
renal dysfunction, and in cases of symptomatic toxicity, dialysis shouldbe instituted. Both intermittent and continuous forms of renal replace-
ment therapy have been effectively utilized to treat gabapentin-induced
neurotoxicity and myoclonic activity [7,15,16]. Although this report
suggests the efﬁcacy of PD in treating gabapentin-induced myoclonus
and neurotoxicity, there are no published data regarding clearance of
gabapentin with PD.
Fourth, pregabalin is an alternative AED with FDA/EMA approval for
pain syndromes (central neuropathic pain, diabetic peripheral neuro-
pathic pain, postherpetic neuralgia, and ﬁbromyalgia) [17]. Pregabalin,
which, like gabapentin, is a branched-chain amino acid AED that is
cleared solely by renal excretion, is also noted to induce myoclonus
[18,19]. Aswith gabapentin, dialysis has been utilized to treat pregabalin
neurotoxicity and myoclonic activity [20,21].
Fifth, a threshold effect for the development of myoclonic activity
with gabapentin and pregabalin has been previously reported [19,22].
This is consistent with the concept that adverse events for speciﬁc
AEDs may require an individual threshold concentration which may
be within the reference range [14,23,24].
Sixth,myoclonus hasmultiple etiologies [25]. Pertinent to these cases
are azotemia and toxic effects of medications. Azotemia was present
in both cases; however, in Case 2, the patient had chronic stable renal
function with the development of myoclonus only after initiation of
gabapentin. Case reports implicate metformin, citalopram, albuterol,
amlodipine, oxycodone, and hydromorphone as potential etiologies for
myoclonus [26–32]. In both cases, the patients had been stable on
these and other admission medications prior to the AKI in Case 1 and
the addition of gabapentin in Case 2.
Seventh, potentially inappropriatemedications (PIMs) are frequently
prescribed in both geriatric patients and patients with chronic kidney
disease [33–35]. In patients at risk for AKI or with ESRD on dialysis,
these cases suggest that gabapentin is a relative PIM unless there is
renal dosing with close monitoring of efﬁcacy and adverse effects.
Pregabalin would also be a relative PIM. In such instances, duloxetine, a
serotonin norepinephrine reuptake inhibitor antidepressant with FDA
approval for diabetic peripheral neuropathic pain and ﬁbromyalgia,
may be an effective treatment option [36].
Eighth, each case hadmultiple potential risk factors for the develop-
ment of myoclonus. In the context of additive risk factors, the probabil-
ity of gabapentin inducing myoclonus was determined by Naranjo's
Adverse Reaction Probability Scale in Case 1 as possible and in Case 2
as probable [37].
There are speciﬁc limitations to this paper. As a case report (N = 2),
the ﬁndings cannot be generalized. Both cases were complicated by the
presence of medical comorbid conditions and speciﬁc medications that
have been implicated as potential etiologies for myoclonus. Gabapentin
drug monitoring was not performed such that the threshold concentra-
tion associated with developing and resolving myoclonus in each case
could not be speciﬁed. Neither case had neuroimaging or EEGs. For eth-
ical reasons, neither patient was rechallenged (Case 1 — maintaining
gabapentin with increased total daily dose of furosemide and addition
of lisinopril; Case 2 — addition of gabapentin); further, the impact of
renal dosing was not assessed in either case. Both patients were lost to
clinical follow-up.
5. Conclusions
Myoclonic activity may occur as a complication of gabapentin toxic-
ity, especially in the setting of renal dysfunction. In the cases reported,
both HD and PD were effective in treating myoclonic activity in acute
and chronic renal dysfunction. Gabapentin requires renal dosing in
patients with chronic kidney disease and in patients at risk for develop-
ing AKI. In cases of symptomatic gabapentin-induced toxicity, dialysis
should be instituted. As gabapentin has multiple indications and off-
label uses, an understanding of myoclonus, neurotoxicity, and renal
dosing is important to clinicians in multiple specialties. Further clinical
education is required.
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